Abstract Number: 0346 • ACR Convergence 2022
Improving Eye Screening Compliance in Patients Taking Hydroxychloroquine in a Community Hospital Setting
Background/Purpose: Hydroxychloroquine (HCQ) is a medication used in most patients with systematic lupus erythematous (SLE). It is generally a safe; however, it can cause retinal…Abstract Number: 0368 • ACR Convergence 2022
Which Are the Best Therapeutic Strategies for Systemic Lupus Erythematosus Severe Thrombocytopenia? A Ten Year Analysis
Background/Purpose: Severe thrombocytopenia in systemic lupus erythematosus (SLE) is characterized by poor response to glucocorticoids and frequent relapses. Information regarding the risk of relapse with…Abstract Number: 0633 • ACR Convergence 2022
Identification of Systemic Lupus Erythematosus Endotypes by Analysis of Inflammatory and Immunologic Gene Expression Signatures
Background/Purpose: One of the hallmarks of SLE is clinical and molecular heterogeneity. Recent work has leveraged next-generation sequencing techniques to identify molecular signatures characteristic of…Abstract Number: 0653 • ACR Convergence 2022
JAK Inhibitors Counteract Cellular Toxicity of Hydroxychloroquine in Vitro
Background/Purpose: Hydroxychloroquine (HCQ) is an anti-malarial medicine and an immunomodulator to treat autoimmune diseases such as systemic lupus erythematosus (SLE) and rheumatoid arthritis (RA). Clinical…Abstract Number: 0674 • ACR Convergence 2022
Prevalence of Heparin Induced Thrombocytopenia in Hospitalized Patients with Antiphospholipid Syndrome or Systemic Lupus Erythematosus with Antiphospholipid Antibodies
Background/Purpose: Thrombosis and thrombocytopenia are defining characteristics of antiphospholipid syndrome (APS), but can also be seen in heparin-induced thrombocytopenia (HIT). Hospitalized patients with APS are…Abstract Number: 0957 • ACR Convergence 2022
Timeliness of Fetal Echocardiography for Congenital Heart Block Detection in Anti-Ro/La-Positive Pregnancies
Background/Purpose: Best practice guidelines recommend screening for congenital heart block (CHB) in anti-Ro/La-positive pregnancies with serial echocardiography starting between 16 to 18 weeks of gestational…Abstract Number: 0978 • ACR Convergence 2022
Belimumab After Rituximab Targets IgA2 Anti-dsDNA Antibody Production and Shifts Repopulating B-cells Towards an Anergic, Non-pathogenic Phenotype in Systemic Lupus Erythematosus
Background/Purpose: The results from the BEAT-lupus trial comparing belimumab vs placebo, both after rituximab in systemic lupus erythematosus (SLE) have recently been reported (1). We…Abstract Number: 0995 • ACR Convergence 2022
Association of Glucocorticoid Use with Healthcare Utilization Among Persons with Systemic Lupus Erythematosus
Background/Purpose: Glucocorticoids (GCs) have long been a mainstay of treatment for systemic lupus erythematosus (SLE). While GCs do provide benefit, there are potential side effects…Abstract Number: 1136 • ACR Convergence 2022
Stratification of Systemic Lupus Erythematosus (SLE) Patients Based on the Molecular Patterns of Mouse Models
Background/Purpose: Systemic lupus erythematosus (SLE) is an autoimmune, chronic and multisystemic autoimmune disorder, which typically affects women and presents high severity and mortality. It is…Abstract Number: 1337 • ACR Convergence 2022
Dietary Mineral Intake of an Inner-City Population and Its Impact on Disease Activity in Patients with SLE
Background/Purpose: Many patients implement a complementary dietary approach in addition to conventional pharmacologic therapy for systemic lupus erythematosus (SLE). There is growing evidence that several…Abstract Number: 1440 • ACR Convergence 2022
Interrelation of T-cell Cytokines and Autoantibodies in Lupus Nephritis: A Cross-sectional Study
Background/Purpose: To determine if different classes of lupus nephritis (LN) are correlated with specific circulating autoantibodies (autoAbs) and T-helper cell cytokines and other manifestations of…Abstract Number: 1456 • ACR Convergence 2022
Latin-American Systemic Lupus Erythematosus Clusters
Background/Purpose: Systemic lupus erythematosus (SLE) is a complex and heterogeneous autoimmune disease. The identification of patient subgroups or clusters may be useful for the management…Abstract Number: 1476 • ACR Convergence 2022
Anti-Neutrophil Extracellular Traps (NET) Antibodies and Their Association with Disease Activity and Clinical Phenotypes in Systemic Lupus Erythematosus
Background/Purpose: Enhanced netosis has been acknowledged as pathogenic in Systemic Lupus Erythematosus (SLE). The presence of antibodies against neutrophil extracellular traps (anti-NETs) in patients with…Abstract Number: 1631 • ACR Convergence 2022
Phospholipase D 4 Is a Novel Surface Marker of a Distinctive B Cell Population Overlapping with Double Negative 2 B Cells
Background/Purpose: Systemic lupus erythematosus (SLE) is an autoimmune disease characterized by various autoantibodies. In particular, targeting autoreactive B cells could be a promising therapy with…Abstract Number: 1711 • ACR Convergence 2022
The Cellular Basis for Type I Interferon Production Following Ultraviolet Light Stimulated Cyclic-GMP-AMP Synthase Activation in the Skin
Background/Purpose: SLE patients characteristically have a type I interferon (IFN-I) signature in peripheral blood cells and this same signature is prominent in lesional and non-lesional…
- « Previous Page
- 1
- …
- 103
- 104
- 105
- 106
- 107
- …
- 181
- Next Page »